$2.25
6.64% today
Nasdaq, Jul 02, 08:49 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Share price

$2.41
-0.57 19.13% 1M
-0.91 27.41% 6M
-0.91 27.41% YTD
-0.73 23.25% 1Y
-26.65 91.71% 3Y
-20.42 89.44% 5Y
-20.42 89.44% 10Y
Nasdaq, Closing price Mon, Jul 01 2024
-0.14 5.49%
ISIN
US15673T1007
Symbol
IPSC
Sector
Industry

Key metrics

Market capitalization $203.65m
Enterprise Value $58.10m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 42.41
P/S ratio (TTM) P/S ratio 148.65
P/B ratio (TTM) P/B ratio 0.88
Sales growth (TTM) Sales growth -76.63%
Turnover (TTM) Turnover $1.37m
EBIT (operating result TTM) EBIT $-124.41m
Free cash flow (TTM) Free cash flow $-98.66m
Cash position $192.02m
EPS (TTM) EPS $-2.22
P/E ratio expected negative
P/S ratio expected 95.93
EV/Sales expected 27.37
Short interest 2.27%
Show more

Is Century Therapeutics Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

Century Therapeutics Inc Share analysis

Unlock Scores for Free

Analyst opinions

5 Analysts have issued a Century Therapeutics Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst opinions

5 Analysts have issued a Century Therapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Century Therapeutics Inc

Dec '23
+/-
%
Net profit -137 -137
4% 4%
-6,101%
Depreciation and amortization 13 13
29% 29%
582%
Share compensation 15 15
37% 37%
653%
Operating cash flow -89 -89
754% 754%
-3,954%
Investments 14 14
55% 55%
613%
Dividend paid - -
-
-
Free cash flow -102 -102
500% 500%
-4,567%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Century Therapeutics Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Century Therapeutics Inc Share News

Positive
Seeking Alpha
12 days ago
Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythemat...
Neutral
GlobeNewsWire
29 days ago
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting
Neutral
GlobeNewsWire
about 2 months ago
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE)
More Century Therapeutics Inc News

Company profile

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Brent Pfeiffenberger
Employees 165
Founded 2018
Website www.centurytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today